e.g. NASCO Products, LLC; Hemp — e.g. GVB Biopharma.
Verified2 deals on this page · sourced from SEC filings
All cross-references covered.
Timeline
2 deals, $5M deployed.
Plotted by close date where disclosed, otherwise announcement. Click any marker to jump to the deal entry.
The playbook
The rationale that repeats.
Three patterns show up across 22nd Century's deal book — what the team buys, how it pays, and how it integrates. The patterns are the throughline; the individual deals below are the evidence.
01
Acquisition criteria
Acquisitions as a regulatory gateway: the NASCO Products deal was driven primari...
Acquisitions as a regulatory gateway: the NASCO Products deal was driven primarily by gaining a federal tobacco manufacturing license and Master Settlement Agreement membership, letting 22nd Century legally make and sell its own products.
NASCO ProductsGVB Biopharma
02
Capital deployment
Stock-heavy consideration: both deals leaned on issuing 22nd Century common shar...
Stock-heavy consideration: both deals leaned on issuing 22nd Century common shares (640,000 for NASCO; 32.9 million for GVB) plus cash and assumed obligations, conserving cash for a company building out new franchises.
NASCO ProductsGVB Biopharma
03
Integration approach
Platform-building M&A: the GVB Biopharma acquisition was framed as a transformat...
Platform-building M&A: the GVB Biopharma acquisition was framed as a transformational, vertically integrated platform meant to more than double revenue and internalize hemp extraction and manufacturing.
NASCO ProductsGVB Biopharma
Deal book · 2 acquisitions
The full deal book.
2 acquisitions. Click any row to see the deal value, financing structure, target revenue, executive commentary, and the original SEC filing — the evidence behind the patterns above.
22nd Century Group acquired all of the membership interests of NASCO Products, LLC, a North Carolina-based federally licensed tobacco product manufacturer and a participating member of the U.S. tobacco Master Settlement Agreement (MSA) since 2005, from sole member Ralph Angiuoli. $250,000 cash plus 640,000 unregistered shares of 22nd Century common stock (subject to reduction for unpaid NASCO liabilities).
Capabilities acquired
Federal tobacco manufacturing licensestanding as a participating manufacturer in the tobacco Master Settlement Agreement (an agreement among 46 statesDC5 territories and the tobacco industry administered by the NAAG)
22nd Century Group acquired substantially all of the assets of GVB Biopharma, a hemp-derived cannabinoid contract development and manufacturing organization (CDMO) believed to be one of the largest global suppliers of hemp-derived active ingredients by tonnage, covering extraction, refinement, conversion, product formulation and API supply. Assumption of ~$4.5M of debt + ~$1.9M of GVB transaction costs + issuance of 32,900,000 unregistered shares of 22nd Century common stock (subject to lock-up).
Capabilities acquired
Proprietary cryogenic hemp extractionrefiningconversion and product formulation technologyactive pharmaceutical ingredient (API) supplylow-cost scalable manufacturingresearch and geneticsregulatory and compliance expertiseinternational capabilities
GVB represents a transformational acquisition for 22nd Century that will enable us to rapidly grow our hemp/cannabis franchise. GVB is one of the largest CBD suppliers globally, possessing innovative, vertically integrated cannabinoid product manufacturing technologies driving industry leading scale and cost efficiency.
James A. MishChief Executive Officer of 22nd Century Group
We are excited to combine with 22nd Century group, pairing our production and manufacturing capabilities together with the best hemp/cannabis plant science in the world.
Phillip SwindellsChief Executive Officer of GVB
Built with VectorShift
Research like this. In three minutes.
Every figure on this page was synthesized by VectorShift from SEC EDGAR filings — before an analyst would finish their first coffee. Point the same pipeline at private deal documents and the output is the same.
VectorShift reads the documents your team actually works on — CIMs, management decks, filings, expert calls, portfolio reports — and returns structured, sourced analysis in minutes, not weeks.